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Abstract
Background: To determine the potential role of 68Ga-PSMA positron emission tomography/computed tomography
(PET/CT) in radiotherapy (RT) planning for prostate cancer (PCa).
Methods: One hundred twenty-nine patients (pts) with 68Ga-PSMA PET/CT were retrospectively analysed. Potentially
influencing factors (androgen deprivation therapy, amount of 68Ga-PSMA-HBED-CC, PSA doubling time ≤/> 10 months,
PSA before PET/CT, T−/N-category and Gleason score) were evaluated by logistic regression analysis. The detection rate
of PSMA PET/CT was compared to contrast enhanced CT and its impact on RT management analysed.
Results: One hundred twenty-nine patients (pts) (20 at initial diagnosis, 49 with PSA relapse and 60 with PSA
persistence after radical prostatectomy) received PSMA PET/CT prior to RT. The majority of pts. (71.3%) had PET-positive
findings (55.1% of pts. with PSA recurrence, 75% of pts. with PSA persistence and 100% of newly diagnosed pts).
Median PSA before PET/CT in pts. with pathological findings (n = 92) was 1.90 ng/ml and without (n = 37) 0.
30 ng/ml. PSA level at time of PET/CT was the only factor associated with PET-positivity. In pts. with a PSA ≤ 0.2 ng/ml,
the detection rate of any lesion was 33.3%, with a PSA of 0.21–0.5 ng/ml 41.2% and with a PSA of 0.51–1.0 ng/ml 69.
2%, respectively. Regarding the anatomic distribution of lesions, 42.2% and 14.7% of pts. with relapse or persistence
had pelvic lymph node and distant metastases. In pts. at initial diagnosis the detection rate of pelvic lymph nodes and
distant metastases was 20% and 10%. 68Ga-PSMA PET/CT had a high detection rate of PCa recurrence outside
the prostatic fossa in pts. being considered for salvage RT (22.4% PET-positive pelvic lymph nodes and 4.1%
distant metastases). Compared to CT, PSMA PET/CT had a significantly higher sensitivity in diagnosing rates of
local recurrence/primary tumour (10.1% vs. 38%), lymph nodes (15.5% vs. 38.8%) and distant metastases (5.4%
vs. 14.0%). This resulted in a modification of RT treatment in 56.6% of pts.
Conclusions: The detection of PCa is strongly associated with PSA level at time of 68Ga-PSMA PET/CT. PSMA
PET/CT differentiates between local, regional and distant metastatic disease with implications for disease management.
PSMA PET/CT allows for tumour detection in post-prostatectomy pts. with PSA ≤ 0.5 ng/ml considered for salvage RT.
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Background
A precise detection and visualisation of disease extent is
of essential importance for indication and target volume
definition in radiotherapy of prostate cancer. Due to lim-
itations in sensitivity and specificity, MRI and choline
PET/CT are not considered precise enough especially at
PSA levels ≤1 ng/ml [1, 2], although both imaging
modalities are as well capable of modifying treatment ap-
proaches [3–7]. Recently, a 68Ga-labelled PSMA-targeted
ligand with high affinity to prostate-specific membrane
antigen (PSMA), a cell surface protein overexpressed
in prostate cancer cells has been introduced for posi-
tron emission tomography (PET) imaging [8–11]. PET
with 68Ga-PSMA demonstrated a superior tumour-to-
background signal intensity and substantially higher
detection rates than have been previously reported for
other imaging modalities in patients with newly diag-
nosed [12–15] or recurrent [3, 16–20] prostate can-
cer. From surgical series, it is known that 68Ga-PSMA
positron emission tomography/computed tomography
(PET/CT) allows for a highly correct identification of
lymph node metastases with a sensitivity and specificity
ranging from 66% to 84% and 82% to 99% [14, 15],
respectively. However, there is a substantial percentage of
prostate cancer patients with a negative 68Ga-PSMA PET/
CT. Bearing this in mind, we tried to determine retro-
spectively which factors correlate with a positive 68Ga-
PSMA PET/CT in patients with primary, persistent or
recurrent prostate cancer. Furthermore, we compared the
detection rate of 68Ga-PSMA PET/CT to contrast
enhanced CT and analysed its impact on the decision-
making process within our department of radiation oncol-
ogy. Several clinical scenarios may be distinguished: A
PET-positive local recurrence within the prostatic fossa
might justify a simultaneous integrated boost and an
additional antiandrogen therapy. Likewise, PET-positive
pelvic lymph node metastases might be treated with an
enlargement of the clinical target volume, a focally higher
dose and antiandrogen therapy. In addition, the evidence
of distant metastases might even cause a non-realisation
of a planned radiotherapy treatment.
Methods
Study population
68Ga-PSMA PET/CT has been routinely offered to
patients for prostate cancer staging before radiotherapy
in our clinic (February 2014–August 2016). A total of
129 patients consecutively received 68Ga-PSMA PET/CT
prior to radiotherapy in different clinical scenarios: 20
patients at initial diagnosis (mostly high-risk patients
with suspected extra-prostatic manifestations), 60 with
biochemical persistence after radical prostatectomy and
49 with biochemical relapse (Table 1). All patients gave
written informed consent to undergo 68Ga-PSMA PET/
CT. This retrospective analysis is in compliance with the
principles of the Declaration of Helsinki and its subse-
quent amendments [21] and was approved by the Ethics
Committee of the LMU Medical Faculty .
PSMA ligand and PET/CT imaging
PSMA-HBED-CC was radiolabelled with 68Ga3+ from a
68Ge/68Ga generator system (GalliaPharm®, Eckert &
Ziegler AG, Berlin, Germany) using an automated
synthesis module (GRP, Scintomics GmbH, Munich,
Germany) and pre-packed cassettes (ABX GmbH,
Radeberg, Germany) as described previously for a
different PSMA ligand by Weineisen et al. [22]. 68Ga-
PSMA PET/CT images extending from the base of
the skull to the mid-thigh were acquired. PET/CT
scan was obtained with intravenous injection of iodine-
containing contrast agent (Ultravist 300, Schering, Berlin,
Germany; or Imeron 300, Bracco, Konstanz; 2.5 mL/s; in
portal venous phase) 60 min after almost simultan-
eous intravenous administration of 20 mg furosemide
and 68Ga-PSMA (median 189 megabecquerel (MBq),
range 87–293). Directly prior to the PET/CT scan,
patients were asked to empty their bladder to minim-
ise tracer accumulation.
Table 1 Patients’ characteristics
Characteristic All pts. Initial
diagnosis
PSA
relapse
PSA
persistence
Number 129 20 49 60
Age (years; median, range) 72 (47–86) 76 (53–86) 74 (50–83) 69 (47–83)
Gleason Score [pts]
6 11 (8.5%) 3 (15%) 7 (14.3%) 1 (1.7%)
7a 27 (20.9%) 3 (15%) 19 (38.8%) 5 (8.3%)
7b 37 (28.7%) 6 (30%) 11 (22.4%) 20 (33.3%)
8 18 (14%) 3 (15%) 7 (14.3%) 8 (13.3%)
9 34 (26.4%) 5 (25%) 5 (10.2%) 24 (40.0%)
10 2 (1.6%) – – 2 (3.3%)
Risk group (D’Amico) [pts]
low 5 (3.9%) 1 (5.0%) 3 (6.1%) 1 (1.7%)
intermediate 21 (16.3%) 2 (10.0%) 13 (26.5%) 6 (10.0%)
high 103 (79.8%) 17 (85%) 33 (67.3%) 53 (88.3%)
PSMA PET positive [pts] 92 (71.3%) 20 (100%) 27 (55.1%) 45 (75%)
PSA PRE-PSMA PET
[ng/ml] (median/
mean, range)
0.86/6.04
(0.13–150.00)
12.4/27.28
(0.14–150.0)
0.49/1.00
(0.15–6.24)
0.99/3.08
(0.13–39.2)
PSA doubling time
≤ 10 months 81 (74.3%) – 21 (42.9%) 60 (100%)
> 10 months 28 (25.7%) – 28 (57.1%) –
ADT at time of PET [pts] 14 (10.9%) 2 (10%) 4 (8.2%) 8 (13.3%)
Activity of 68Ga-PSMA-
HBED-CC [MBq]
(mean, range)
190.43
(87–293)
197.50
(100–293)
192.07
(94–293)
186.85
(87–286)
(Pts patients, PSA prostate specific antigen, ADT androgen deprivation
therapy, MBq Mega-Becquerel)
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Image interpretation
PET/CT was interpreted by a consensus read of one nu-
clear medicine physician and one radiologist. Location of
lesions was each determined by CT. PET-positive lesions
were identified by 68Ga-PSMA uptake visually above
background and not associated with the physiologic up-
take. CT-positive nodes were defined by increased short
axis diameter, loss of fatty hilum, or increased contrast
enhancement. Bone metastases were detected by suspi-
cious sclerotic lesions, visceral metastases by suspicious
hypodense or hyperdense lesions in the respective organ.
Based on PET/CT images and reports, stage according to
PET or CT was documented separately by one nuclear
medicine physician and one radiation oncologist [23].
Statistical analysis
Demographic and tumour characteristics were analysed.
The association between positive 68Ga-PSMA PET/CT
findings and possibly interacting variables, like androgen
deprivation therapy (ADT) at the time of PET/CT,
amount of injected tracer, PSA-level, PSA doubling time,
T−/N-category and Gleason score was assessed by uni-
variate and multivariate logistic regression analysis. P
values <0.05 were considered statistically significant.
PSA before PET/CT was classified in eight steps (≤
0.2 ng/ml – > 20 ng/ml). Gleason score was grouped in
six different classes (GS 5/6, GS 7a, GS 7b, GS 8, GS 9
and GS 10), T-category in four (T1 – T4) and N-
category in three classes (N0, N1, Nx). Injected tracer
amount was evaluated as multiples of 100 MBq. Patients
after radical prostatectomy were classified by PSA doub-
ling time ≤ vs. > 10 months. PET/CT positive findings
(primary tumour/local recurrence, lymph node and dis-
tant metastases) are presented separately according to
the respective treatment indication prior to radiotherapy.
The detection rate of residual tumour, recurrence or
newly diagnosed disease comparing PET/CT to CT ex-
clusively as well as change in radiotherapy management
was analysed by Fisher’s test.
Results
A total of 129 patients (20 at initial diagnosis, 60 with
biochemical persistence and 49 with biochemical relapse
after radical prostatectomy) consecutively received 68Ga-
PSMA PET/CT prior to radiotherapy (Table 1). Most
patients (71.3%) had 68Ga-PSMA PET/CT-positive find-
ings: Patients with biochemical recurrence had the low-
est detection rate (55.1%) followed by patients with
biochemical persistence (75%). At initial diagnosis, all
patients (100.0%) had 68Ga-PSMA PET/CT-positive
findings. Overall, the predominant GS, T- and N-
category were 7b, T3 and N0 – in newly diagnosed pa-
tients prior to definitive radiotherapy 7b, cT1/cT3 and
cN0, in patients with biochemical relapse 7a, pT2 and
pN0 and in patients with biochemical persistence 9, pT3
and pN1, respectively. Altogether, most patients had a
high-risk prostate cancer (79.8%) according to D’Amico
risk group classification [24]. PSA doubling time in post-
prostatectomy patients differed between patients with
biochemical recurrence having mainly a PSA doubling
time > 10 months (57.1%) versus patients with biochemical
persistence having a PSA doubling time ≤ 10 months
(100%). ADT was in use in 14 patients at the time of 68Ga-
PSMA PET/CT. Median PSA before 68Ga-PSMA PET/CT
was 12.4 ng/ml in newly diagnosed patients, 0.99 ng/ml in
patients with biochemical persistence and 0.49 ng/ml in
patients with biochemical recurrence.
Factors predicting 68Ga-PSMA PET/CT positive findings
Patients with pathological radiotracer uptake (n = 92;
Table 2) had a median PSA of 1.90 ng/ml (range 0.14–
150.0), a PSA doubling time of mainly ≤10 months
(77.8%), mainly a T3 N0 prostate cancer, a predominant
GS 9 (29.3%) and ongoing ADT at time of PET in 12
patients. They were injected with a mean activity of
191.96 MBq 68Ga-PSMA-HBED-CC (range 87–293) and
were mainly high-risk patients (81.5%). Patients without
pathological findings (n = 37; Table 2) had a median
PSA of 0.30 ng/ml (range 0.13–3.24), a PSA doubling
Table 2 Patient characteristics: PET positive vs. PET negative
Characteristic PET positive PET negative
Number 92 37
Age (years) at PSMA PET
(median, range)
72 (49–86) 72 (47–80)
Gleason Score [pts]
6 8 (8.7%) 3 (8.1%)
7a 19 (20.7%) 8 (21.6%)
7b 23 (25.0%) 14 (37.8%)
8 13 (14.1%) 5 (13.5%)
9 27 (29.3%) 7 (18.9%)
10 2 (2.2%) –
Risk group (D’Amico) [pts]
low 3 (3.3%) 2 (5.4%)
intermediate 14 (15.2%) 7 (18.9%)
high 75 (81.5%) 28 (75.7%)
PSA PRE-PSMA PET [ng/ml]
(median/mean, range)
1.90/8.27 (0.14–150.0) 0.30/0.50 (0.13–3.24)
PSA doubling time
≤ 10 months 56 (77.8%) 25 (67.6%)
> 10 months 16 (22.2%) 12 (32.4%)
ADT at time of PET [pts] 12 (13.0%) 2 (5.4%)
Activity of 68Ga-PSMA-HBED-
CC [MBq] (mean, range)
191.96 (87–293) 186.78 (94–293)
(Pts patients, PSA prostate specific antigen, ADT androgen deprivation therapy,
MBq Mega-Becquerel)
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time of mainly ≤10 months (67.6%), mainly a T3 N0
prostate cancer and a predominant GS 7b. Mean activity
of 68Ga-PSMA-HBED-CC radiotracer was 186.78 MBq
(range 94–293) in PET-negative patients with patients
being mostly high-risk patients (75.7%) and two patients
having ongoing ADT at the time of PET scan. In the
univariate analysis (Table 3) no significant difference was
found between PET-positive and PET-negative patients
regarding the use of ADT at time of PET (p = 0.222), the
injected amount of 68Ga-PSMA-HBED-CC (p = 0.590),
the PSA doubling time ≤/> 10 months (p = 0.517),
GS (p = 0.285) and T- (p = 0.982) and N-category
(p = 0.987). Concerning PSA before PET, a significant
difference was found (p < 0.001). In the multivariate
analysis, the significant association between a PET-
positive result and PSA level a time of PET persisted
(p = 0.002). Figures 1 and 2 demonstrate the prob-
ability of pathological 68Ga-PSMA PET/CT depend-
ing on PSA level at time of PET/CT and GS. There
is an almost linear increase of PET-positive result
with rising PSA level: Patients with PSA ≤ 0.2 ng/ml
had a detection rate of 33.3%, patients with PSA
0.21 ≤ 0.5 ng/ml a rate of 41.2% and patients with
PSA 0.51 ≤ 1.0 ng/ml a rate of 69.2%.
Tumour location and PET versus CT-positive findings
Prior to definitive radiotherapy, 68Ga-PSMA PET/CT
showed suspicious lesions within the prostate gland in
90% of patients and suspicious pelvic lymph nodes and/
or distant metastases in 20%/10% of the patients, re-
spectively. 68Ga-PSMA PET/CT had a high detection
rate of prostate cancer recurrence outside the prostatic
fossa in patients being considered for salvage radiother-
apy: 22.4% of patients had PET-positive pelvic lymph
nodes and 4.1% distant metastases. Both patients with
distant metastases had also local recurrence exclusively
without evidence of pelvic lymph node metastases. In
patients considered for salvage radiotherapy with a
PSA < 0.5 ng/ml (25 patients), 68Ga-PSMA PET/CT
detected in 16.0% local recurrences within the prostatic
fossa and in 20.0% PET-positive pelvic lymph nodes. In
patients with postoperatively biochemical persistence,
PET/CT revealed a high number of lymph node metas-
tases (58.3%), distant metastases (23.3%) and macro-
scopic residual tumour (21.7%). Seventeen of 60 patients
with persistent PSA after radical prostatectomy had a
pre-PSMA PET/CT PSA <0.5 ng/ml. Of these
patients, there was one patient (5.9%) with macro-
scopic residual tumour, 7 patients with pelvic lymph
node metastases (41.2%) and 1 patient with distant
metastases (5.9%). The single patient with bone
metastases had pelvic lymph node involvement as
well. Figure 3 shows a lesion based analysis of PET-
positive local recurrence/primary tumour, PET-
Table 3 Univariate and multivariate analysis of factors
predicting 68Ga-PSMA PET/CT positive findings
Association between PET
positive results and
Present (yes/no) p-Valuea p-Valueb
ADT No 0.222 0.321
Activity of 68Ga-PSMA-
HBED-CC [MBq]
No 0.590 0.843
PSA PRE-PSMA PET Yes <0.001* 0.002*
PSA doubling time ≤/>
10 months
No 0.517 0.942
Gleason Score No 0.285 0.482
(PSA prostate specific antigen, ADT androgen deprivation therapy,
MBq Mega-Becquerel)
aunivariate and bmultivariate binary logistic regression analysis
*p < 0.05 statistically significant
Fig. 1 Probability of a pathological 68Ga-PSMA PET/CT depending
on PSA levels in 129 patients. Corresponding table shows the rates
of PET/CTs with/without pathological radiotracer uptake in %
according to PSA level
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positive lymph node and distant metastases according
to sub-grouping of patients and contains additional
information on simultaneous involvement of local
recurrent tumour/primary tumour, lymph node metas-
tases and/or distant metastases. 68Ga-PSMA PET/CT
as medical imaging modality had a significantly higher
diagnostic value in the detection of suspicious lesions
within the prostate/prostatic fossa (38% vs. 10.1%;
p < 0.05), of suspicious pelvic lymph nodes (38.8% vs.
15.5%; p < 0.05) and distant metastases (14.0% vs.
5.4%; p < 0.05) compared to the contrast enhanced
CT scan acquired during PET/CT imaging. This
resulted in a modification of radiotherapy treatment in
56.6% of patients by e.g. enlarged target volumes or
simultaneously integrated boost volumes. Figure 4 demon-
strates the integration of 68Ga-PSMA PET/CT images into
radiation therapy planning in three patients.
Discussion
This heterogeneous group of patients with primary,
recurrent or persistent prostate cancer represents a
typical cohort referred to radiation oncology depart-
ments. We are thus confident that our findings are of
relevance in clinical practice.
In general, out of 129 patients with high-risk primary,
persistent or recurrent prostate cancer, PSMA-PET
revealed a least one relevant lesion in 71.3% of the
cohort. This rate compares nicely to the number of
PET-positive patients (82.8%) in the study of Afshar-
Oromieh et al. [16]: a similarly heterogeneous group of
patients with progressive disease after initial treatment (e.g.
radiotherapy and/or surgery; n = 292), before initiation of
local therapy (n = 27) or before therapy with radiolabelled
PSMA ligands (n = 38) was analysed.
The clear correlation of PSA level and probability of
detection was seen in our analysis (Fig. 1) as well as in
the data provided by Ceci et al. [25] (n = 70), Afshar-
Oromieh et al. [16] (n = 292) and Eiber et al. [17]. Ac-
cordingly, patients with biochemical recurrence having
the lowest PSA levels prior to PSMA PET/CT had the
lowest detection rate (55.1%) compared to patients with
persistent (75%) or primary prostate cancer (100%).
At present, PSA levels ≤0.2 ng/ml are frequently
judged in postoperative patients to be non-critical,
nevertheless one-third of our patients (33.3%) had
PET-positive findings even below a PSA of 0.2 ng/ml.
This rate drastically increased up to 69.2% in patients
with a PSA level between 0.51–1.0 ng/ml. Thus,
PSMA PET/CT detects early local recurrence or
metastatic disease and possibly allows for a more
effective and early treatment.
Apart from PSA-level before PET/CT, multivariate
analysis detected no significant associations between a
positive PSMA PET/CT and any of the other factors
including ADT, amount of injected tracer, PSA doubling
time, and Gleason score. This finding is well in accord-
ance with the observations provided by Afshar-Oromieh
et al. [16] regarding PSA doubling time and Gleason
score. In contrast, Afshar-Oromieh et al. reported a
positive association between detection rate and ongoing
ADT. In animal models and in vitro cell culture experi-
ments, ADT increases PSMA expression which might
contribute to improved detection rate by 68Ga-PSMA
PET/CT [26–30]. However, at present the complex asso-
ciation between an ADT driven increase of PSMA up-
take in the individual tumour lesion, the ADT driven
reduction of global tumour load and the final PET signal
is not completely understood. In our opinion, the use of
ADT in a cohort with mostly high-risk prostate cancer
patients as evaluated by Afshar-Oromieh et al. is also
a surrogate for high tumour burden and high PSA
levels. We therefore counsel our patients to start with
Fig. 2 Probability of a pathological 68Ga-PSMA PET/CT depending
on GS in 129 patients. Corresponding table shows the rates of PET/CTs
with/without pathological radiotracer uptake in % according to GS class
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ADT after PSMA PET/CT if planned. Unlike the
aforementioned trials, Ceci et al. also observed a
significant association between PSA doubling time
and PSMA PET/CT positivity [25]. This might be
explained by the fact that Ceci et al. coded PSA
doubling time as continuous variables whereas in our
trial and the trial of Afshar-Oromieh et al. PSA doub-
ling time was analysed in distinct categories.
Compared to CT, sensitivity of PSMA PET/CT was
significantly higher for local findings (38.0% vs.
10.1%), pelvic lymph nodes (38.8% vs. 15.5%) and
distant failure (14.0% vs. 5.4%). This observation
perfectly mirrors the findings reported by Giesel el al.
showing that PSMA PET/CT is significantly more
sensitive than CT-based 3D–volumetric lymph node
evaluation [18].
Furthermore, we analysed the question how far an
increased detection rate leads to a change in therapeutic
management. In our series, PSMA PET/CT-positive
findings had a substantial influence on the therapeutic
concept in 56.6% of the patients with implication on
either adaptation of treatment volumes, dose concepts
or the commencement of hormone ablation therapy.
This compares nicely to similar analyses [19, 31–33] all
Fig. 3 Lesion based analysis (PET-positive local recurrence/primary tumour and PET-positive lymph node and distant metastases) according to
sub-grouping of patients (patients before definitive RT at initial diagnosis, patients before salvage RT with PSA recurrence, patients before Salvage
RT with PSA < 0.5 ng/ml, patients before additive RT with PSA persistence, patients before additive RT with PSA persistence with PSA < 0.5 ng/ml)
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reporting major modifications of therapeutic manage-
ment in 33.3% - 53.7% of the patients.
At present, PSMA PET/CT is widely regarded as the
best modality for lymph node staging in a primary as
well as in a postoperative setting [14, 34]. Data provided
by van Leeuwen et al. [19] suggest that the level of
lymph node positivity has been strongly underestimated
in the pre-PSMA PET/CT era. In their analysis, lymph-
atic recurrences outside the prostatic fossa occurred in
20% of patients scheduled for salvage radiotherapy with
additional 10% of distant metastases detected in
PSMA PET/CT. Bearing in mind that currently only
target volumes covering the prostatic fossa are
routinely employed [35], a substantial rate of lymph
node metastases is not treated. This is supported by
our own data showing that even below a PSA level of
0.5 ng/ml, PSMA PET/CT still detected 20.0% of
pelvic lymph node metastases in patients with salvage
radiotherapy indication.
The documented need to treat PSA relapses as early as
possible (even below PSA levels of 0.2 ng/ml) and the fact
that the diagnostic sensitivity is optimal above a PSA level
of 0.5 ng/ml currently creates an inherent dilemma. Since
all data available consistently document that PSA control
is significantly better when radiotherapy is commenced as
early as possible [36, 37], it is not justified to wait until
PSA is in an optimal diagnostic range. Our strategy to
cope with this dilemma is therefore to employ PSMA
PET/CT in patients even around 0.2 ng/ml especially
whenever high-risk features are present. Like the ana-
lysis by Henkenberens et al. on 29 patients with bio-
chemical recurrence receiving an individualized
radiotherapy treatment plan based on PSMA PET/CT
findings [38], target volumes are modified accordingly
in our institution after critical assessment. Neverthe-
less, keeping the sensitivity and specificity rates from
surgical series in mind, PSMA PET/CT might still
underestimate the true extent of disease and should
therefore from our point of view not result in an
omission of nomogram [39] triggered radiotherapy
treatment volumes.
At present, legal constraints prohibit the use of PSMA
in truly prospective studies in Germany. Despite the clear
limitations of retrospective approaches, the available data
from several analyses strongly underline the high value of
PSMA-PET/CT for staging as well as for treatment strati-
fication in patients with primary high-risk, persistent or
recurrent carcinoma of the prostate.
Fig. 4 Radiotherapy treatment planning in three patients based on PSMA PET/CT information. 68Ga-PSMA PET/CT (B, D, F) and target volumes
with simultaneously integrated boost volumes (A, C, E) are shown. Figs. A and B show a patient with PSA recurrence and evidence of lymph node
metastasis in 68Ga-PSMA PET/CT who was treated with a simultaneously integrated boost to the lymph node. Figs. C and D show a patient with PSA
recurrence due to local relapse in the region of the former prostate gland. This local relapse was treated with a simultaneously integrated boost
volume. Figs. F and E show a patient with singular osseous metastasis that was treated with a simultaneously integrated boost
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Conclusions
In this retrospective study, we showed that the detection
of prostate cancer is strongly associated with PSA level
at time of Ga-PSMA PET/CT. Better than any other
imaging modality, PSMA PET/CT differentiates local, re-
gional and distant metastatic disease with considerable im-
plications for disease management. In post-prostatectomy
patients with rising PSA ≤ 0.5 ng/ml with indication for
salvage radiotherapy, PSMA PET/CT is narrowing the
diagnostic gap as until now the gradual PSA increase often
occurred long before recurrent disease could be localized
clinically or by imaging.
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